Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial

导出原文传递

翻译打印收藏纠错

作者： Mei, Qian ^[1] ; Zhang, Wenying ^[2] ; Liu, Yang ^[3] ; Yang, Qingming ; Rasko, John E. J. ; Nie, Jing ; Liu, Jiejie ; Li, Xiang ; Dong, Liang ; Chen, Meixia ; Zhang, Yan ; Shi, Lu ; Wu, Huitao ; Han, Weidong

作者单位： Royal Prince Alfred Hosp, Dept Cell & Mol Therapies, Camperdown, NSW, Australia ^[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Biotherapeut, Beijing, Peoples R China ^[2] Chinese Peoples Liberat Army Gen Hosp, Natl Engn Lab Med Big Data Applicat Technol, Beijing ^[3]

发布时间 2021-07-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2020年26卷17期

4521-4530页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除